| Characteristic | Total n* | All patients (n = 827) | Subset 1† (n = 423) | Subset 2† (n = 395) |
| Age (years) | 823 | 49 (17–95) | 49 (17–82) | 49 (18–95) |
| Female gender | 826 | 51% | 51% | 52% |
| Ethnicity | 589 | |||
| Caucasian | 68% | 66% | 70% | |
| African–American | 6% | 6% | 5% | |
| Hispanic | 24% | 26% | 22% | |
| Asian Pacific Islander | 2% | 2% | 3% | |
| Body mass index (kg/m2) | 604 | 33 (21–60) | 33 (21–60) | 33 (21–59) |
| <25 | 3% | 3% | 3% | |
| 25–29 | 23% | 22% | 24% | |
| 30–39 | 58% | 58% | 57% | |
| >/ = 40 | 16% | 17% | 16% | |
| Hypertension | 652 | 60% | 56% | 65% |
| Diabetes mellitus | 749 | 35% | 32% | 38% |
| HbA1c (%) | 461 | 5.9 (3.8–13.5) | 5.9 (3.9–13.5) | 5.9 (3.8–12.7) |
| Diabetics | 6.7 (3.9–13.5) | |||
| Non-diabetics | 5.5 (3.8–10.5) | |||
| Fasting glucose (mg/dl) | 331 | 104 (69–339) | 103 (69–284) | 105 (75–339) |
| Hyperlipidaemia | 736 | 42% | 41% | 43% |
| QUICKI | 345 | 0.308 (0.239–0.440) | 0.308 (0.240–0.440) | 0.306 (0.239–0.406) |
| ⩾0.35 | 9% | 9% | 9% | |
| 0.30–0.35 | 54% | 54% | 54% | |
| <0.30 | 37% | 37% | 37% | |
| Alanine aminotransferase (ALT) (U/l) | 785 | 69 (9–769) | 69 (10–420) | 69 (9–769) |
| Aspartate aminotransferase (AST) (U/l) | 785 | 48 (11–445) | 48 (11–313) | 48 (15–445) |
| AST/ALT ratio | 785 | 0.7 (0.3–3.7) | 0.7 (0.3–3.7) | 0.7 (0.4–3.7) |
Values are medians with ranges shown in parentheses.
*Number of patients with available measured parameters.
†BARD score validation subsets 1 and 2 are each approximately 50% of the total sample.